Logo Medical Science Monitor

Call: +1.631.470.9640
Mon - Fri 10:00 am - 02:00 pm EST

Contact Us

Logo Medical Science Monitor Logo Medical Science Monitor Logo Medical Science Monitor

09 September 2002

Cytotoxic effect of cyclosporin A alone and in combination with 2-chlorodeoxyadenosine against P388 murine leukemia in vivo

Grażyna Józefowicz-Okonkwo, Anna Szmigielska-Kapłon, Tadeusz Robak

Med Sci Monit 2002; 8(9): BR373-377 :: ID: 13268

Abstract

Summary
Background: The purpose of our study was to determine the antileukemic effects of cyclosporin A (CsA) and its interaction with a new purine analogue, 2-chlorodeoxyadenosine (2-CdA, cladribine)
on P388 murine leukemia in vivo.
Material/methods: Mice were engrafted intraperitoneally (i.p.) with 106 P388 leukemia cells on day 0 of each step of the two-step experiment. All treatments were initiated on the next day (day 1) as daily i.p. injections and lasted for five consecutive days. In the first part of the experiment, designed to establish the antileukemic effect of CsA, the mice received 10, 15, 20, 25 or 30 mg/kg of CsA.
In the second part, where the interaction between CsA and 2-CdA was examined, the animals were administered CsA at a dose of 15 mg/kg, or 2-CdA at a dose of 20 mg/kg, or CsA combined with 2-CdA at the same doses as in monotherapy.
Results: CsA did not influence the survival time of mice with P388 leukemia at any dose. CsA was used for the interaction study at a dosage of 15 mg/kg, as this was best tolerated by the animals.
The mice treated with combination therapy using CsA and 2-CdA survived longer than those treated with 2-CdA monotherapy (p=0.00015).
Conclusion: Our study revealed that CsA alone does not increase the survival time of mice with P388 leukemia, but it augments the antileukemic effect of 2CdA.

Keywords: Antineoplastic Combined Chemotherapy Protocols - therapeutic use, Cladribine - administration & dosage, Cyclosporine - administration & dosage, Drug Synergism, Immunosuppressive Agents - administration & dosage, Neoplasm Transplantation, Neoplasms - drug therapy, Purines - metabolism, Time Factors, Tumor Cells, Cultured

Add Comment 0 Comments

528 7

Editorial

01 June 2023 : Editorial  

Editorial: Infectious Disease Surveillance Using Artificial Intelligence (AI) and its Role in Epidemic and Pandemic Preparedness

Dinah V. Parums
Science Editor, Medical Science Monitor, International Scientific Information, Inc., Melville, NY, USA

DOI: 10.12659/MSM.941209

Med Sci Monit 2023; 29:e941209

0:00

In Press

08 Jun 2023 : Clinical Research  

Risk Factors for New Vertebral Compression Fracture After Percutaneous Vertebral Augmentation: A Retrospect...

Med Sci Monit In Press; DOI: 10.12659/MSM.940134  

08 Jun 2023 : Clinical Research  

A Nomogram for Identifying HR+/Her2- Breast Cancer Patients with Positive Sentinel Lymph Nodes and Omitted ...

Med Sci Monit In Press; DOI: 10.12659/MSM.940124  

08 Jun 2023 : Clinical Research  

Burden of COVID-19 on Mental Health of Resident Doctors in Poland

Med Sci Monit In Press; DOI: 10.12659/MSM.940208  

08 Jun 2023 : Clinical Research  

Risk Prediction for Rapidly Progressive Interstitial Lung Disease in Anti-MDA5-Positive Dermatomyositis: Th...

Med Sci Monit In Press; DOI: 10.12659/MSM.940251  

Most Viewed Current Articles

13 Nov 2021 : Clinical Research  

Acceptance of COVID-19 Vaccination and Its Associated Factors Among Cancer Patients Attending the Oncology ...

DOI :10.12659/MSM.932788

Med Sci Monit 2021; 27:e932788

0:00

30 Dec 2021 : Clinical Research  

Retrospective Study of Outcomes and Hospitalization Rates of Patients in Italy with a Confirmed Diagnosis o...

DOI :10.12659/MSM.935379

Med Sci Monit 2021; 27:e935379

08 Mar 2022 : Review article  

A Review of the Potential Roles of Antioxidant and Anti-Inflammatory Pharmacological Approaches for the Man...

DOI :10.12659/MSM.936292

Med Sci Monit 2022; 28:e936292

01 Jan 2022 : Editorial  

Editorial: Current Status of Oral Antiviral Drug Treatments for SARS-CoV-2 Infection in Non-Hospitalized Pa...

DOI :10.12659/MSM.935952

Med Sci Monit 2022; 28:e935952

Your Privacy

We use cookies to ensure the functionality of our website, to personalize content and advertising, to provide social media features, and to analyze our traffic. If you allow us to do so, we also inform our social media, advertising and analysis partners about your use of our website, You can decise for yourself which categories you you want to deny or allow. Please note that based on your settings not all functionalities of the site are available. View our privacy policy.

Medical Science Monitor eISSN: 1643-3750
Medical Science Monitor eISSN: 1643-3750